MYNZ - Mainz Biomed N.V. Annual Revenue Growth (Last Twelve Months)

Is it worth investing in Mainz Biomed N.V. (MYNZ), considering its ESG contribution through non-invasive diagnostics? The last twelve months (LTM) revenue growth rate provides the answer, where the current status is 0.00. Mandatory colon screenings via the ColoAlert system ensure a stable cash flow. However, operating income is only just beginning to emerge, and financial stability currently relies on funds from previous investment rounds.
Mainz Biomed NV (MYNZ) - metric breakdowns and financial figures

A fundamental risk assessment requires an analysis of revenue dynamics, where the current YoY TTM revenue growth rate measures operational resilience by comparing total sales over the last 12 months with the same period last year. For Mainz Biomed N.V. (MYNZ), this indicator reflects the effectiveness of the ColoAlert system's commercial implementation and the expansion of insurance reimbursements, allowing investors to separate market noise from the actual scaling of high-margin kit sales.